share_log

康方生物：根據一般授權配售新股

AKESO: PLACING OF NEW SHARES UNDER GENERAL MANDATE

香港交易所 ·  Mar 20 19:56
Summary by Moomoo AI
康方生物科技（開曼）有限公司（「康方生物」）於2024年3月21日宣布，公司已與配售代理Morgan Stanley Asia Limited及中信里昂證券有限公司簽訂配售協議，條件性同意以每股47.65港元的價格配售24,800,000股新股。該配售價較3月20日的收市價50.70港元折讓約6.02%，並較前五個交易日的平均收市價51.13港元折讓約6.81%。配售股份相當於公司現有已發行股本的約2.95%，及配售後擴大的已發行股本的約2.86%。假設配售股份全數認購，公司將籌得約1,181.72百萬港元，扣除相關費用後，淨額約為1,170.18百萬港元。所得款項將主要用於研發、產品商業化及一般企業用途。配售完成須待聯交所上市委員會批准配售股份上市及買賣，並須滿足配售協議所載條件。本次配售將不會在美國進行，且配售股份將根據一般授權發行，無需股東批准。
康方生物科技（開曼）有限公司（「康方生物」）於2024年3月21日宣布，公司已與配售代理Morgan Stanley Asia Limited及中信里昂證券有限公司簽訂配售協議，條件性同意以每股47.65港元的價格配售24,800,000股新股。該配售價較3月20日的收市價50.70港元折讓約6.02%，並較前五個交易日的平均收市價51.13港元折讓約6.81%。配售股份相當於公司現有已發行股本的約2.95%，及配售後擴大的已發行股本的約2.86%。假設配售股份全數認購，公司將籌得約1,181.72百萬港元，扣除相關費用後，淨額約為1,170.18百萬港元。所得款項將主要用於研發、產品商業化及一般企業用途。配售完成須待聯交所上市委員會批准配售股份上市及買賣，並須滿足配售協議所載條件。本次配售將不會在美國進行，且配售股份將根據一般授權發行，無需股東批准。
Kangfang Biotechnology (Cayman) Limited (“Kangfang Biotech”) announced on 21 March 2024 that it has entered into a distribution agreement with its distribution agents Morgan Stanley Asia Limited and CITIC Lion Securities Limited, conditionally agreeing to sell 24,800,000 new shares at a price of HK$47.65 per share. The share price represents a decrease of approximately 6.02% from the closing price of HK$50.70 on March 20 and a decrease of approximately 6.81% from the average closing price of HK$51.13 over the previous five trading days. The allotment represents approximately 2.95% of the Company's existing issued share capital and approximately 2.86% of the extended issued share capital after the distribution. Assuming total subscriptions for the distribution of shares, the Company will raise approximately HK$1,181.72 million, net of approximately HK$1,170.18 million...Show More
Kangfang Biotechnology (Cayman) Limited (“Kangfang Biotech”) announced on 21 March 2024 that it has entered into a distribution agreement with its distribution agents Morgan Stanley Asia Limited and CITIC Lion Securities Limited, conditionally agreeing to sell 24,800,000 new shares at a price of HK$47.65 per share. The share price represents a decrease of approximately 6.02% from the closing price of HK$50.70 on March 20 and a decrease of approximately 6.81% from the average closing price of HK$51.13 over the previous five trading days. The allotment represents approximately 2.95% of the Company's existing issued share capital and approximately 2.86% of the extended issued share capital after the distribution. Assuming total subscriptions for the distribution of shares, the Company will raise approximately HK$1,181.72 million, net of approximately HK$1,170.18 million, net of related expenses. Proceeds will be used primarily for R&D, product commercialization and general corporate purposes. Completion of the distribution is subject to approval by the Listing Committee of the Exchange of Exchange for the listing and sale of the shares and subject to the conditions set out in the distribution agreement. This distribution will not take place in the United States and the shares will be issued under general authorization without shareholder approval.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more